CN Patent

CN105919955A — 一种鲁索利替尼制剂及其应用

Assigned to Foshan City Teng Rui Medicine Technology Co Ltd · Expires 2016-09-07 · 10y expired

What this patent protects

本发明公开了一种鲁索利替尼制剂及其应用,它是由鲁索利替尼、乳糖、微晶纤维素以及药学上可以接受的载体制备而成。可以获得流动性、稳定性、溶出度较好的鲁索利替尼制剂，从而适合工业化大生产。本发明的治疗中间或高危骨髓纤维化,包括原发性骨髓纤维化，真性红细胞增多症后骨髓纤维化和原发性血小板增多症后骨髓纤维化患者的药物组合，配比合理，可以快速释放药物，对所述病症能产生很好的疗效。

USPTO Abstract

本发明公开了一种鲁索利替尼制剂及其应用,它是由鲁索利替尼、乳糖、微晶纤维素以及药学上可以接受的载体制备而成。可以获得流动性、稳定性、溶出度较好的鲁索利替尼制剂，从而适合工业化大生产。本发明的治疗中间或高危骨髓纤维化,包括原发性骨髓纤维化，真性红细胞增多症后骨髓纤维化和原发性血小板增多症后骨髓纤维化患者的药物组合，配比合理，可以快速释放药物，对所述病症能产生很好的疗效。

Drugs covered by this patent

Patent Metadata

Patent number
CN105919955A
Jurisdiction
CN
Classification
—
Expires
2016-09-07
Drug substance claim
No
Drug product claim
No
Assignee
Foshan City Teng Rui Medicine Technology Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.